

Uses of Heparin other than Anticoagulation

Essay

Submitted for Partial Fulfillment of Master Degree
in critical care medicine

By

Nehad Salah Ibrahim Gad

M. B., B.Ch

Under supervision of

Prof. Dr. Hoda Omar Mahmoud

Professor of Anesthesiology and Intensive Care Medicine
Faculty of Medicine – Ain Shams University

Dr. Waleed Ahmed Mansour

Lecturer of Anesthesiology and Intensive Care Medicine
Faculty of Medicine – Ain Shams University

Dr. Heba Abd El-Azeem Labib

Lecturer of Anesthesiology and Intensive Care Medicine
Faculty of Medicine – Ain Shams University

Faculty of Medicine
Ain shams University
2012



﴿ قَالُوا سُبْحَنَكَ لَا عِلْمَ لَنَا إِلَّا مَا

عَلَّمْتَنَا إِنَّكَ ^صأَنْتَ الْعَلِيمُ الْحَكِيمُ ﴿٣٢﴾

صدق الله العظيم

(سورة البقرة ، الآية ٣٢)

Acknowledgment

"Praise be to **ALLAH**, Who guided us to this;
and in no way could we have been guided,
unless Allah has guided us".

(Al A'raf: 43)

I would like to express my sincere thanks to Prof. Dr./ Hoda Omar Mahmoud , Professor of Anesthesia and Intensive Care Unit, Faculty of Medicine, Ain Shams University for her supervision, guidance, valuable advice, helpful directions and continuous interest throughout the whole work,

My extreme thanks and gratefulness to Dr./ Walid Ahmed Mansour , Lecturer of Anesthesia and Intensive Care Unit, Faculty of Medicine, Ain Shams University for his keen interest, beneficial advice, constant support and scientific opinions during the conduction of the operative phase of this work,

I also wish to offer my warmest and deep appreciation to Dr./ Heba Abd El Azeem Labib ,Lecturer of Anesthesia and Intensive Care Unit, Faculty of Medicine, Ain Shams University for her unlimited, endless help and continuous encouragement.

Contents	Page
Introduction	1-2
Aim of the work	3
Physiology of hemostasis and Pharmacology of heparin	4-44
Uses of heparin as anticoagulant	45-60
Uses of heparin other than anticoagulation	61-100
Summary	101-102
References	103-123
Arabic Summary	124-125

List of Tables

Item	Content	Page
Table (1)	Coagulation Factors	6
Table (2)	Pharmacokinetic and Biophysical Limitations of Heparin	19
Table (3)	Features of Heparin- Induced Thrombocytopenia	21
Table (4)	Management of Heparin-Induced Thrombocytopenia	23
Table (5)	Molecular weight (MW) data and anticoagulant activities of currently available LMWH products	27
Table (6)	Advantages of Low-Molecular-Weight Heparin and Fondaparinux over Heparin	35
Table (7)	Comparison of the Features of Heparin, Low-Molecular-Weight Heparin, and Fondaparinux	37

List of Figures

Item	Content	Page
Fig. (1)	Basic representation of the elements of hemostasis	4
Fig. (2)	The pathway of contact system of blood coagulation	9
Fig. (3)	Coagulation cascade	12
Fig. (4)	The repeated disaccharide unit of heparin	16
Fig. (5)	Structure of fondaparinux	36
Fig.(6)	Mechanism of action of heparin , LMWH and fondaparinux	41

List of abbreviations

AMI	Acute myocardial infarction
AT	Anti thrombin
APLA	Anti phosphor lipid antibody syndrome
APTT	Activated partial thromboplastin time
ASM	Airway smooth muscle
CA	Calcium
CF	Cystic fibrosis
CFRT	Cystic fibrosis trans membrane conductance regulator
CN	Cyanide
CO	Carbon monoxide
CPU	Carboxypeptidase
Cu	Copper
DVT	Deep venous thrombosis
DIC	Disseminated intra vascular coaguability
ECM	Extra cellular matrix
FGF	Fibroblast growth factor
FIO2	Fraction of inspired oxygen
GAGs	Glycos amino glycans
HIT	Heparin induced thrombocytopenia
HIV	Human immuno deficiency virus
HMWK	High molecular weight kininogen
Hr	Hour
HSPGs	Heparan sulfate proteo glycans
IDS	Iduronate sulfate
IgG	Immuno globulin G
IL	Interleukin
INR	International normalized ratio
IPC	International pneumatic compression
IU	International unit
IV	Intravenous
KDa	Kilo Dalton
Kg	Kilogram
LDL	Low density lipoprotein

LMWH	Low molecular weight heparin
MI	Millileter
P/F Ratio	Arterial oxygen content / fraction of inspired oxygen ratio
PCI	Percutaneous coronar intervention
PE	Pulmonary embolism
PF4	Platelet factor 4
PK	Pre kallekrin
PO	Per oral
rhAT	Recombinant human anti thrombin
RVT	renal vein thrombosis
SC	Sub cutaneous
SGN	N-Sulfo-glucosamine -6-sulfate
TAFI	thrombin activatable fibrinolysis inhibitor
Tat	Trans activating factor
TFPI	Tissue factor pathway inhibitor
TPN	Total parenteral nutrition
TxA2	Thromboxane A2
U/Kg	Unit per kilogram
UFH	Unfractionated heparin
VLDL	Very low density lipoproteins
VTE	Venous thrombo embolism
VWF	Von Willebrand fctor
WBPTT	Whole blood partial thromboplastin time

Introduction